top of page
Search
BrickBio Achieves Stable Cell Line in Record Timeframe: 5x Faster with 7x Enhanced Production
BOSTON, February 7, 2023 /PRNewswire/ -- BrickBio Highlights Unique Advantages from the Proprietary "VADER" System, published on Dec 22,...
jamesitalia
Feb 8, 20233 min read
781 views
0 comments
BrickBio Unveils Powerful Engineered RNA Therapeutic Modification Platform at AACR 2022
BOSTON, April 25, 2022 /PRNewswire/ -- BrickBio Highlights Powerful Advantage of the Company's BrickADCs™, Protein Origami™, and...
jamesitalia
Apr 25, 20223 min read
742 views
0 comments
BrickBio Announces Rapid V2, eCLIC™, Chemistry and Cytokine External Partner Collaboration
BOSTON, Nov. 2, 2021 /PRNewswire/ -- BrickBio, the leader in site-specific bioconjugation, announced a rapid next-generation conjugation...
jamesitalia
Nov 2, 20212 min read
622 views
0 comments
World's First Antibody Drug Conjugate (ADC) Rapid Predictive SiteSelect™ Panel Launched
BOSTON, Oct. 26, 2021 /PRNewswire/ -- A Rapid Predictive Site-Selection Panel for ADC-Linker-Payload Optimization BrickBio, the leader in...
jamesitalia
Oct 27, 20213 min read
448 views
0 comments
BrickBio Creates Novel Class of Bispecific Antibody Drug Conjugate and Receives Green Light
BOSTON, Jan. 19, 2021 /PRNewswire/ -- The leader in site specific bioconjugation and DAR (drug to antibody ratio) optimization in...
BrickBio
Jan 29, 20212 min read
644 views
0 comments
BrickBio Enters into Antibody Drug Conjugate (ADC) Co-Development Partnership with Large Pharma
BOSTON, Jan. 6, 2021 /PRNewswire/ -- BrickBio, the leading company in site-specific bioconjugation for improved therapeutics, has signed...
BrickBio
Jan 29, 20212 min read
706 views
0 comments
BrickBio Announces Data on First Preclinical Antibody for Breast and Gastric Cancer
The company is developing biologics across three internal programs BOSTON, Nov. 10, 2020 /PRNewswire/ -- The leading company in...
BrickBio
Nov 10, 20203 min read
645 views
0 comments
BrickBio Validates Its Novel Therapeutic Conjugation Platform at Commercial Scale
BrickBio has made robust its novel site-specific conjugation process of inserting unnatural amino acids at any site within a protein or...
BrickBio
Sep 2, 20202 min read
263 views
0 comments
BrickBio Expands Space to Accommodate Pharma Partnerships and Pipeline Development
BOSTON, Jan. 22, 2020 /PRNewswire/ -- BrickBio Inc., the leading company in site specific, single and multi-site bioconjugation of...
BrickBio
Jan 30, 20202 min read
427 views
0 comments
Abcam & BrickBio announce partnership to incorporate conjugation-ready sites across Abcam portfolio
- BrickBio’s technology enables efficient placement of unnatural amino acids into recombinant antibodies at specific sites - Together,...
BrickBio
Nov 8, 20193 min read
627 views
0 comments
BrickBio Presents Novel Conjugation Chemistry & Unveiled Protein Therapeutic Program at World ADC
Boston, Massachusetts – BrickBio, a protein engineering company formed out of the Chatterjee Lab at Boston College and backed by Tiger...
BrickBio
Oct 18, 20192 min read
397 views
0 comments
Dr. James Italia Joins BrickBio as Vice President of Commercial Development
Boston, Massachusetts – BrickBio, the Tiger Gene backed protein and antibody modification company, announced today that Dr. James Italia,...
BrickBio
Jun 13, 20192 min read
704 views
0 comments
BrickBio Obtains Exclusive License to “Pan Epitope” Site-Specific Antibody and Protein Modification
Boston, Massachusetts - BrickBio, a company formed out of Tiger Gene has obtained a worldwide exclusive license, from Boston College, to...
BrickBio
Apr 12, 20191 min read
521 views
0 comments
bottom of page